vs
IOVANCE BIOTHERAPEUTICS, INC.（IOVA）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
STURM RUGER & CO INC的季度营收约是IOVANCE BIOTHERAPEUTICS, INC.的1.7倍（$151.1M vs $86.8M），IOVANCE BIOTHERAPEUTICS, INC.同比增速更快（17.7% vs 3.6%），STURM RUGER & CO INC自由现金流更多（$12.3M vs $-61.9M），过去两年IOVANCE BIOTHERAPEUTICS, INC.的营收复合增速更高（1001.6% vs 5.1%）
艾欧万斯生物治疗公司是一家总部位于加利福尼亚州圣卡洛斯的生物制药初创企业，专注于开发针对癌症的肿瘤浸润淋巴细胞（TIL）疗法，致力于为癌症患者提供创新型的免疫治疗方案。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
IOVA vs RGR — 直观对比
营收规模更大
RGR
是对方的1.7倍
$86.8M
营收增速更快
IOVA
高出14.1%
3.6%
自由现金流更多
RGR
多$74.2M
$-61.9M
两年增速更快
IOVA
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $86.8M | $151.1M |
| 净利润 | — | — |
| 毛利率 | 67.4% | 17.8% |
| 营业利润率 | -84.7% | 2.3% |
| 净利率 | — | — |
| 营收同比 | 17.7% | 3.6% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | — | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IOVARGR
| Q4 25 | $86.8M | $151.1M | ||
| Q3 25 | $67.5M | $126.8M | ||
| Q2 25 | $60.0M | $132.5M | ||
| Q1 25 | $49.3M | $135.7M | ||
| Q4 24 | $73.7M | $145.8M | ||
| Q3 24 | $58.6M | $122.3M | ||
| Q2 24 | $31.1M | $130.8M | ||
| Q1 24 | $715.0K | $136.8M |
净利润IOVARGR
| Q4 25 | — | — | ||
| Q3 25 | $-91.3M | $1.6M | ||
| Q2 25 | $-111.7M | $-17.2M | ||
| Q1 25 | $-116.2M | $7.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-83.5M | $4.7M | ||
| Q2 24 | $-97.1M | $8.3M | ||
| Q1 24 | $-113.0M | $7.1M |
毛利率IOVARGR
| Q4 25 | 67.4% | 17.8% | ||
| Q3 25 | 43.0% | 15.1% | ||
| Q2 25 | 5.5% | 3.9% | ||
| Q1 25 | -0.8% | 22.0% | ||
| Q4 24 | 68.7% | 22.8% | ||
| Q3 24 | 46.2% | 18.5% | ||
| Q2 24 | -0.8% | 22.3% | ||
| Q1 24 | — | 21.5% |
营业利润率IOVARGR
| Q4 25 | -84.7% | 2.3% | ||
| Q3 25 | -140.7% | -2.7% | ||
| Q2 25 | -189.8% | -15.6% | ||
| Q1 25 | -245.8% | 6.2% | ||
| Q4 24 | -117.5% | 7.8% | ||
| Q3 24 | -152.1% | 3.1% | ||
| Q2 24 | -327.6% | 6.9% | ||
| Q1 24 | -16464.6% | 5.5% |
净利率IOVARGR
| Q4 25 | — | — | ||
| Q3 25 | -135.3% | 1.2% | ||
| Q2 25 | -186.2% | -13.0% | ||
| Q1 25 | -235.5% | 5.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -142.7% | 3.9% | ||
| Q2 24 | -312.2% | 6.3% | ||
| Q1 24 | -15800.8% | 5.2% |
每股收益（稀释后）IOVARGR
| Q4 25 | — | $0.22 | ||
| Q3 25 | — | $0.10 | ||
| Q2 25 | $-0.33 | $-1.05 | ||
| Q1 25 | $-0.36 | $0.46 | ||
| Q4 24 | $-0.24 | $0.62 | ||
| Q3 24 | $-0.28 | $0.28 | ||
| Q2 24 | $-0.34 | $0.47 | ||
| Q1 24 | $-0.42 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $297.0M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $698.6M | $283.8M |
| 总资产 | $913.2M | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IOVARGR
| Q4 25 | $297.0M | $92.5M | ||
| Q3 25 | $300.8M | $80.8M | ||
| Q2 25 | $301.2M | $101.4M | ||
| Q1 25 | $359.7M | $108.3M | ||
| Q4 24 | $323.8M | $105.5M | ||
| Q3 24 | $397.5M | $96.0M | ||
| Q2 24 | $412.5M | $105.6M | ||
| Q1 24 | $356.2M | $115.3M |
股东权益IOVARGR
| Q4 25 | $698.6M | $283.8M | ||
| Q3 25 | $702.3M | $279.6M | ||
| Q2 25 | $698.5M | $289.3M | ||
| Q1 25 | $767.9M | $321.5M | ||
| Q4 24 | $710.4M | $319.6M | ||
| Q3 24 | $773.5M | $314.9M | ||
| Q2 24 | $768.5M | $321.5M | ||
| Q1 24 | $680.0M | $332.0M |
总资产IOVARGR
| Q4 25 | $913.2M | $342.0M | ||
| Q3 25 | $904.9M | $342.3M | ||
| Q2 25 | $907.4M | $349.5M | ||
| Q1 25 | $966.7M | $379.0M | ||
| Q4 24 | $910.4M | $384.0M | ||
| Q3 24 | $991.1M | $373.5M | ||
| Q2 24 | $964.3M | $376.7M | ||
| Q1 24 | $869.8M | $385.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-52.6M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $-61.9M | $12.3M |
| 自由现金流率自由现金流/营收 | -71.3% | 8.2% |
| 资本支出强度资本支出/营收 | 10.7% | 2.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-336.2M | $38.5M |
8季度趋势，按日历期对齐
经营现金流IOVARGR
| Q4 25 | $-52.6M | $15.5M | ||
| Q3 25 | $-78.7M | $12.9M | ||
| Q2 25 | $-67.4M | $14.7M | ||
| Q1 25 | $-103.7M | $11.1M | ||
| Q4 24 | $-73.3M | $20.0M | ||
| Q3 24 | $-59.0M | $9.4M | ||
| Q2 24 | $-98.4M | $18.7M | ||
| Q1 24 | $-122.3M | $7.3M |
自由现金流IOVARGR
| Q4 25 | $-61.9M | $12.3M | ||
| Q3 25 | $-89.5M | $7.0M | ||
| Q2 25 | $-74.9M | $9.1M | ||
| Q1 25 | $-109.9M | $10.0M | ||
| Q4 24 | $-77.5M | $16.4M | ||
| Q3 24 | $-61.3M | $2.6M | ||
| Q2 24 | $-98.9M | $10.1M | ||
| Q1 24 | $-126.5M | $5.6M |
自由现金流率IOVARGR
| Q4 25 | -71.3% | 8.2% | ||
| Q3 25 | -132.7% | 5.5% | ||
| Q2 25 | -124.9% | 6.9% | ||
| Q1 25 | -222.8% | 7.4% | ||
| Q4 24 | -105.1% | 11.2% | ||
| Q3 24 | -104.6% | 2.1% | ||
| Q2 24 | -317.9% | 7.7% | ||
| Q1 24 | -17685.3% | 4.1% |
资本支出强度IOVARGR
| Q4 25 | 10.7% | 2.1% | ||
| Q3 25 | 16.1% | 4.6% | ||
| Q2 25 | 12.4% | 4.2% | ||
| Q1 25 | 12.6% | 0.8% | ||
| Q4 24 | 5.7% | 2.5% | ||
| Q3 24 | 3.9% | 5.5% | ||
| Q2 24 | 1.4% | 6.6% | ||
| Q1 24 | 583.4% | 1.3% |
现金转化率IOVARGR
| Q4 25 | — | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
